Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Myeloma XII (ACCoRd trial)
ISRCTN10038996Phase 3Active, not recruiting
- Sponsor
- University of Leeds
- Start
- Mar 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
01
Overview
Phase 3, randomised, open-label trial of ixazomib, thalidomide, dexamethasone and melphalan in multiple myeloma (MM) (4 arms), sponsored by University of Leeds. Primary endpoints: Overall response rate following ASCT and Progression-free survival. Started Mar 2017; status: active, not recruiting.
02
Drugs
ixazomibthalidomidedexamethasonemelphalan
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ISRCTN10038996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN10038996.